Leukemia
Description
This issue of <em>Emerging Cancer Therapeutics</em> provides a comprehensive review for practitioners on the current status of leukemia treatment. Leukemia treatment has undergone major change over the course of the past few years and <em>Leukemia</em> addresses current best practices in the light of the most recent evidence.
With contributions from experts across the US and Canada, <em>Leukemia</em> details the current management of different types of leukemia and reviews new therapies in development for various forms of acute leukemia, chronic leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Coverage includes new developments in hematopoitic cell transplantation, leukemia pathology and management, immunotherapy and targeted therapies. It is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows.
<ul>Emerging Cancer Therapeutics Series Titles Features: <li>Editorial board of nationally recognised experts across the spectrum of Cancer Therapeutics <li> <li>In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics </li> <li>Issues edited by an authority in specific subject area </li> <li>Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience </li> <li>Emphasises multidisciplinary approaches to research and practice </li> </ul>More details
Persons
<strong>Uday Popat, MD, MRCP, FRCPath, FACP</strong>. Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX
<strong>Jame Abraham, MD</strong>. Bonnie Wells Wilson Distinguished Professor and Eminent Scholar, Chief, Section of Hematology-Oncology, Medical Director, Mary Babb Randolph Cancer Centre West Virginia University